Sinopharm, Sinovac to Test Developed COVID-19 Vaccine against Omicron

Leading Chinese drug-makers Sinopharm and Sinovac developed a vaccine targeted Omicron variant that was approved for clinical trials in Hong Kong.

The new vaccine is based on doses of both vaccines, as Sinovac contains dead sample of Coronavirus, and another doses of Sinopharm.

The developed vaccine will be tested in adults who received two or three doses of the vaccine without specifying any vaccination-type requirements for the participants.

A new study cited by Reuters on Friday showed  that a new protein-based Sinopharm COVID-19 vaccine’s booster shot showed high efficiency against Omicron, a new study cited by Reuters on Friday.

The three Sinopharm shots reflected a stronger antibody reaction against the latest variant than the earlier shots.

Raising concerns over the Chinese vaccine response to Omicron, Sinopharm revealed the study to enhance people’s trust in the second-emerged COVID-19 vaccine globally.

In the same context, an earlier study showed a BBIBP-CorV booster expressed neutralization against this strain in Wuhan.

The study,  conducted by Shanghai Jiao Tong University, compared the response of the vaccine towards Omicron and the older variants.